Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes. We enrolled 34 patients onto a phase 2 trial of capecitabine, gemcitabine, and bevacizumab. Median progression-free survival was 5.5 months, median overall survival was 12 months, and objective response rate was 20%. This regimen is an option in sRCC; however, response rates are low. Novel therapies are needed. Background: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factore targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. Patients and Methods: Patients with metastatic or unresectable sRCC were eligible for inclusion. Patients received oral capecitabine 800 mg/m 2 twice daily on days 1 to 21 of a 28-day cycle, intravenous gemcitabine 900 mg/m 2 on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15. Primary end points were progression-free survival and time to treatment failure (TTF). Secondary end points were safety, objective response rate, and overall survival. Results: Thirty-four patients were enrolled onto the trial. One patient was excluded from survival analysis and 4 from response analysis as a result of missing data. Median progression-free survival was 5.5 months (95% confidence interval [CI], 3.4-7.7), median TTF was 4.2 months (95% CI, 2.4-6.0), and median overall survival was 12 months (95% CI, 10.6-13.4). Objective response rate was 20% (5 partial responses, 1 complete response), and disease control rate was 73%. Thirty-one (91%) of the 34 patients discontinued treatment. The most common reason for treatment discontinuation was progressive disease, which occurred in 24 patients (71%). The most common grade 3 toxicity was rash (including handefoot syndrome) in 24% patients. Conclusion: The combination of capecitabine, gemcitabine, and bevacizumab is an option for patients with sRCC; however, response rates are low. Novel therapies are needed to improve outcomes in patients with sRCC.
Introduction
Renal-cell carcinoma (RCC) is the most common primary neoplasm of the kidney, with a worldwide incidence of over 330,000 new cases annually. 1 Sarcomatoid differentiation of RCC is characterized by spindle-cell morphology and has been reported to occur in 1% to 29% of cases. [2] [3] [4] It has been suggested to represent clonal evolution and can involve any histologic subtype of RCC. [5] [6] [7] [8] Sarcomatoid features classify RCC as Fuhrman grade 4 tumors; these typically have higher Ki-67 as well as frequent p53 mutations. [8] [9] [10] [11] Sarcomatoid RCC (sRCC) has an aggressive biology and confers a 3-fold higher risk of mortality compared to clear-cell RCC. 2, 12, 13 Nearly half of patients with sRCC present with metastatic disease and consequently have a poor prognosis, with a median overall survival (OS) of 3 to 10 months. 12, 14, 15 Disease of patients with sRCC has historically shown limited response to treatment, and prospective trials with small numbers of patients have shown poor response rates. 14, [16] [17] [18] [19] [20] [21] Despite recent advances in targeted therapies, experience with these agents in sRCC has been limited. Recent phase 3 trials have either excluded or have not specified details of inclusion of sRCC. [22] [23] [24] [25] [26] [27] Rapid growth and pathologic resemblance with sarcomas have generated interest in cytotoxic chemotherapy similar to the ones used in soft-tissue sarcomas, with anecdotal reports of durable responses with doxorubicin-based regimens. [28] [29] [30] [31] [32] The chemotherapy combination of infusional fluorouracil and weekly gemcitabine in metastatic RCC demonstrated an overall response rate of 17% in the phase 2 setting and was regarded as a therapeutic option in the early days of targeted therapy development. 33 Similar results have been reported for capecitabine and gemcitabine, with response rates of 8% to 16% in metastatic RCC. [34] [35] [36] Preclinical data have shown overexpression of hypoxia-inducible factor pathway markers in sRCC. 37 Vascular endothelial growth factor (VEGF)-targeted therapy has shown variable results, with partial response (PR) rates of 10% to 20%, stable disease (SD) in nearly 50%, and OS of 10 to 12 months, with concerns for worse outcomes with higher component of sarcomatoid element. 14, 38, 39 At the time of study development, bevacizumab was regarded as a promising antiangiogenic agent and was being used in several combination regimens in the treatment of metastatic RCC. 40 The aim of this phase 2 trial was to evaluate outcomes in patients with sRCC treated with the combination of cytotoxic chemotherapy and antiangiogenic therapy.
Patients and Methods
This was a single-arm, open-label, single-center, phase 2 trial of capecitabine, gemcitabine, and bevacizumab for the treatment of metastatic or unresectable sRCC (ClinicalTrials.gov identifier: NCT00496587). The trial was approved by the institutional review board at the University of Texas MD Anderson Cancer Center and complied with the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws. Written informed consent was obtained from patients at the time of enrollment.
Eligibility
Adult patients with metastatic or unresectable sRCC were enrolled onto this trial. Eligible patients had at least 10% sarcomatoid histology on the tumor specimens (nephrectomy or metastasectomy); patients could have any World Health Organizationerecognized RCC epithelial component. Histologic evaluation was done by a dedicated expert genitourinary pathologist at the trial site. Patients diagnosed with sRCC via needle biopsy of the primary or a metastatic site were eligible, regardless of the percentage of sarcomatoid dedifferentiation found in the biopsy sample. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate renal, hepatic, hematologic, and cardiac function; and at least 1 site of measurable disease. Patients should not have received any prior cytotoxic chemotherapy or bevacizumab. Prior sorafenib, sunitinib, or immunotherapy treatment was permitted.
Treatment Plan
Patients received oral capecitabine 800 mg/m 2 twice daily on days 1 to 21, intravenous gemcitabine 900 mg/m 2 over 30 minutes on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15 of a 28-day cycle for a planned total of 12 cycles. The dose of individual agents was determined on the basis of our retrospective and phase 2 experience. 35, 41 Growth factors were allowed at the discretion of the treating physician. Surgical consolidation, when appropriate, was allowed for patients with responsive disease. Dose reductions for capecitabine and gemcitabine, and interruptions were allowed on the basis of prespecified adverse events (AEs) (Supplemental Table 1 in the online version).
Diagnostic Evaluation and Assessment of Efficacy and Safety
Patients were evaluated at baseline with a history and physical examination; laboratory studies; urinalysis; 12-lead electrocardiogram; and computed tomographic scans of chest, abdomen, and pelvis. Imaging studies were performed every 8 weeks. Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. 42 Progression was defined as per RECIST as an increase in disease burden by 20% or more in the sum of the largest tumor diameters compared to baseline or smallest measurement. AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
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Study End Points and Statistical Analysis
A maximum accrual of 40 patients was planned. The primary end point was progression-free survival (PFS) and time to failure (TTF), with failure defined as death, disease progression, or unacceptable toxicity. Objective response rate (ORR) and OS were secondary end points. PFS, TTF, and OS were calculated from the first day of treatment. Early stopping rules were established for both TTF and AEs (Supplemental Methods in the online version). Descriptive statistics were used to summarize continuous and categorical variables. Kaplan-Meier curves were constructed by SPSS 23.0 software (IBM SPSS, Chicago, IL). The chi-square test was used to compare the proportion of categorical variables between groups. P values of < .05 were considered statistically significant.
Results
Patient Characteristics
The study opened for enrollment in July 2007 and was terminated in January 2012 as a result of low accrual after enrollment of 34 patients. Thirty-three patients were included in the final survival analysis. One patient went off protocol after receiving 1 cycle of therapy, the result of a delay in starting his second cycle, and was never restaged, and as a result of missing data was not included in the survival analysis. Patient characteristics and prior therapies are summarized in Table 1 . Two patients were treated with sorafenib before initiation of the study; both had outright progressive disease (PD). Three patients received sunitinib before initiation of the study; 2 of these patients received sunitinib in the first-line setting and 1 in the second-line setting. In the first-line sunitinib patients, one had SD as best e48 -Clinical Genitourinary Cancer February 2018
Phase 2 Trial in Sarcomatoid RCC response and the other had PD. The second-line patient was treated with temsirolimus before receiving sunitinib, and experienced SD on sunitinib for some time before disease progression.
Treatment Administration and Safety
Thirty-four patients had evaluable safety data. The median number of cycles administered was 5 (range, 1-12 days). During the study period, there were 594 AEs, regardless of causality. Of these, 377 were thought to be related (possibly, probably, or definitely) to the study regimen (Table 2) . No grade 4 toxicity was reported. The most common nonhematologic AEs were pain (body, limb, head) in 82% of patients, rash (including handefoot syndrome) in 76% of patients, and fatigue in 65% of patients. The most common hematologic AEs were anemia in 38% of patients and lymphopenia in 15% of patients. The most common grade 3 toxicities were rash in 24% patients, fatigue in 9% of patients, and catheter-related thrombosis in 6% of patients. Twelve patients required dose reductions of 1 or more. One patient died suddenly of an unknown cause while enrolled onto the study. At the time of last follow-up, only 1 patient was still alive.
Efficacy
Thirty-four patients were treated according to the study protocol. Thirty-three patients had data evaluable for survival analysis ( Figure 1 ). Four patients could not be evaluated for response by diagnostic imaging because they discontinued treatment after a single cycle. Best responses in 30 patients with evaluable data included complete response (CR) in 1 patient, PR in 5 patients, SD in 16 patients, and PD in 8 patients. In terms of the primary end points of the study, the median PFS was 5.5 months (95% confidence interval [CI], 3.4-7.7), and the median TTF was 4.2 months (95% CI, 2.4-6.0). In terms of the secondary end points of the study, the ORR was 20% (6/30), and the disease control rate (CR þ PR þ SD) was 73% (22/30). Median OS was 12 months (95% CI, 10.6-13.4). Three patients completed the study per protocol after receiving 12 cycles of chemotherapy. Thirty-one (91%) of the 34 patients discontinued treatment. Reasons for discontinuation were PD in 24 patients (71%), toxicity in 2 patients (6%; acute congestive heart failure in one patient and grade 3 handefoot syndrome in the other), patient choice in 2 cases (6%), other reasons in 2 cases (6%; one patient had acute kidney injury unrelated to the investigational regimen, and the other patient had a treatment delay per protocol), and sudden death of unknown cause in 1 patient (3%). Among patients with data evaluable for response, the disease control rate between groups with 20% versus > 20 sarcomatoid element was 71% (5/7) and 73% (8/11), respectively (P ¼ .95). No patients went on to receive consolidative surgery in this cohort.
Discussion
We demonstrated the feasibility of and objective response with combined cytotoxic and antiangiogenic therapy in patients with sRCC. The ORR was 20%, median TTF was 4.2 months, and median OS was 12 months. These results are comparable with the phase 2 trial by Michaelson et al 16 that used sunitinib and gemcitabine in 39 patients with sRCC, which showed an ORR of 26%, a median time to progression (TTP) of 5 months, and a median OS of 10 months. The most common grade 3/4 toxicities encountered were neutropenia (51%), anemia (28%), and fatigue (21%). Conversely, the most common grade 3 toxicities in our cohort were rash in 24% of patients, fatigue in 9%, and catheter-related thrombosis in 6%. There were no grade 4 toxicities in our cohort. A summary of studies reporting on systemic treatments in sRCC is provided in Supplemental Table 2 in the online version. The 
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Clinical Genitourinary Cancer February 2018 -e49 14 patients who had < 20% sarcomatoid elements in their tumor fared better with VEGF-targeted therapy; however, the differences were not statistically significant. The PRs in their patients were limited to this population, and they had better PFS (6.8 vs. 4.3 months) and OS (14.9 vs. 8.6 months) compared to those who had > 20% sarcomatoid elements. 14 In our cohort, there was no difference in the disease control rate between patients with 20% versus > 20% sarcomatoid elements. However, the number of patients was very small. These results suggest that patients with a higher degree of sarcomatoid component (more than 20%-25%) may not benefit from single-agent VEGF-targeted therapy. At the time of this trial design, data supporting the 20% to 25% prognostic cutoff were not available. Thus, while patients with > 10% sarcomatoid component were included on our trial, Treatment-related adverse events were defined as events that the investigators deemed to have a possible, probable, or definite relationship to the study regimen. Listed are the treatment-related adverse events that were reported in at least 5% of the patients, along with any incidence of grade 3 or 4 events in more than 1% of the study population. Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; PTT ¼ partial thromboplastin time.
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analysis of outcomes incorporated a 20% cutoff. Epithelial-tomesenchymal transition has been reported as one of the mechanisms involved in such resistance to anti-VEGF therapies in sarcomatoid tumors. 44, 45 One retrospective study from our institution on 108 patients by Mian et al 15 showed response rates of 32%, 33%, and 14% to interferon-ae, interleukin-2e, and interferon-gebased regimens, respectively. However, there was considerable heterogeneity in the treatment regimens, many of which included cytotoxic agents such as 5-flurouracil, mitomycin C, cyclophosphamide, vincristine, doxorubicin, and dacarbazine. The higher grade, proliferation index, and rapid growth of the sarcomatoid component in sRCC can partly explain the susceptibility to such cytotoxic agents noted in the present report and in prior studies. A difficulty in this study was patient accrual, largely because this tumor is so rare. It is an unfortunate reality that rare and orphan tumors are often treated with data gleaned from case series and retrospective analysis. Multicenter collaboration is essential to gather larger cohorts of patients with rare tumors and to perform prospective studies in order to better understand disease biology and advance the field.
Ongoing trials in patients with sRCC or advanced RCC with sarcomatoid features are currently evaluating sunitinib with or without gemcitabine (NCT01164228), pazopanib (NCT01767636), sorafenib with bevacizumab (NCT00126503), and sunitinib versus bevacizumab with atezolizumab (NCT02420821). sRCC has among the highest expression of c-MET among the different RCC subtypes, making it an excellent candidate for clinical trials involving cabozantinib. 46 There is also higher coexpression of programmed death ligand 1 (PD-L1) on tumor cells, as well as programmed death 1 (PD-1), on tumorinfiltrating lymphocytes in sRCC compared to clear-cell RCC (50% vs. 3%) 47 making antiePD-1/PD-L1 checkpoint inhibitors an attractive option in sRCC. Phase 1 data with atezolizumab, a PD-L1 antibody, showed early evidence of antitumor activity in sRCC with an ORR of 22%; safety data indicated a favorable profile, with no grade 4 or 5 events. Further studies of immune checkpoint inhibition are needed in sRCC, both as single-agent and combination therapy options. 48 
Conclusion
The combination of capecitabine, gemcitabine, and bevacizumab was well tolerated in patients with sRCC and resulted in PFS, ORR, and OS comparable to other regimens tested in this population. Further studies must establish the optimal combination of cytotoxic chemotherapy, targeted agents, and immunotherapy to improve outcomes in these patients.
Clinical Practice Points
Patients with sRCC have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and VEGF-targeted therapies. In this phase 2 trial of capecitabine, gemcitabine, and bevacizumab including 34 patients, the median PFS was 5.5 months, median OS was 12 months, ORR was 20%, and disease control rate was 73%. The most common grade 3 toxicity was rash. There were no grade 4 toxicities. Therapy with capecitabine, gemcitabine, and bevacizumab is an option for patients with sRCC; however, response rates are low. Future studies need to evaluate combination of cytotoxic, antiangiogenic, and immunotherapy in sRCC.
Supplemental Methods
Dose Reduction
Treatment was interrupted in the following events:
Hemorrhagic complication, defined as hemorrhage that is lifethreatening at the time of occurrence. Thromboembolic complication, excluding catheter-related thrombosis. Included were stroke, myocardial infarction, transient ischemic attack, and angina. Absolute neutrophil count (ANC) < 1000/mL. Platelet count < 100,000/mL. Any nonhematologic toxicity of National Cancer Institute (NCI) grade 3 or worse if clinically significant. Grade 2 handefoot syndrome. Grade 2 mucositis. Grade 2 pneumonitis. Grade 2 diarrhea, at physician discretion.
For interruptions caused by myelosuppression, treatment could be resumed with capecitabine and gemcitabine given at the next lower dose level (Supplemental Table 1 in the online version) when ANC has recovered to > 1500/mL and platelet count has recovered to > 100,000/mL.
For interruptions caused by diarrhea, mucositis, or handefoot syndrome, treatment could be resumed with gemcitabine at the same dose level and capecitabine given at the next lower dose level (Supplemental Table 1 in the online version) when improved to NCI grade 1 or less.
Patients with grade 2 pneumonitis related to gemcitabine, or patients with hemorrhagic or thromboembolic complications were removed from the study. For all other nonhematologic toxicity NCI grade 3 or worse, treatment could be resumed with gemcitabine and capecitabine at the next lower dose level when toxicity had resolved to NCI grade 2 or less.
Capecitabine Dose Reduction for Renal Insufficiency. Patients were required to have creatinine clearance > 50 mL/min at protocol entry, for which no dose reduction was required (or 30-50 mL/min with initial dose reduction). Patients who experienced a decrease in creatinine clearance to 50 mL/min or less required reduction of capecitabine by one dose level, even if there was no grade 3 toxicity. However, this was only be a one-time dose reduction to compensate for the decrease in renal clearance of capecitabine. Patients with calculated creatinine clearance < 30 mL/min were removed from the study.
Bevacizumab Dosing for Proteinuria. In the event of proteinuria > 2 g per 24 hours, bevacizumab was held until proteinuria improved to < 2 g, and gemcitabine and capecitabine were continued. If the 24-hour urine did not improve to < 2 g within 2 weeks, the patient was removed from the study.
Pneumonitis Related to Gemcitabine. If pneumonitis grade 2 or higher developed in a given cycle and was related to gemcitabine, gemcitabine was promptly discontinued and the patient was removed from the study. Treatment with corticosteroids was provided according to established guidelines.
Days of interruption were counted as missed treatment days and did not alter the treatment schedule.
Patients with creatinine clearance of 30 to 50 mL/min were eligible with an initial dose reduction of capecitabine to the (À1) dose level (Supplemental Table 1 in the online version).
Model for Futility Monitoring
The median of the time to treatment failure (TTF), denoted by m, had a targeted minimum of 4 months. Failure was defined as death or disease progression or unacceptable toxicity. Patients were evaluated for disease progression every 8 weeks. Under a Bayesian model, we assumed that TTF is exponentially distributed with median m, which in turn has an inverse gamma prior with mean 4 months and variance 10. On the basis of the historical mean serious adverse event (SAE) rates of 15% at 3 months, 25% at 6 months, and 30% at 9 months, we assumed that the time to a serious adverse event (TSAE) is distributed according to a Weibull distribution characterized by ProbðTSAE > tÞ ¼ expfÀmtag, which has a decreasing rate over time. Both m and a were assumed to follow gamma distributions, with prior mean .07444 and variance .0006 for m and prior mean .72715 and variance .06 for a.
The trial would be terminated early for futility if a median TTF of at least 4 months was unlikely, formally if Prðl > 4jdataÞ < :075.
Because the historical 6-month SAE rate was 25%, the trial would be terminated early for safety, equivalently due to an excessive SAE rate, if PrðPrfSAE during first 6 monthsg>:25jdataÞ Supplemental 
